What is the primary route of administration for Alemtuzumab in treating Multiple Sclerosis?

Alemtuzumab is primarily administered via intravenous (IV) infusion for the treatment of multiple sclerosis (MS). This method of administration allows for a controlled and steady delivery of the medication directly into the bloodstream, which is crucial for ensuring the effectiveness of the drug, as it targets specific immune cells implicated in the pathophysiology of MS.

IV infusion is particularly beneficial for Alemtuzumab because it can be given in a clinical setting where patients can be monitored for any potential adverse reactions during and after the infusion. This is important due to the risk of infusion-related reactions and potential long-term side effects associated with the medication.

Other routes of administration, such as oral tablets, intramuscular injections, and subcutaneous injections, are not applicable for Alemtuzumab, as they do not achieve the same level of bioavailability or therapeutic effect for this specific treatment. In summary, the choice of IV infusion for Alemtuzumab aligns with the required therapeutic approach in managing MS effectively.